Two projects submitted by the Company to the grant call announced by the Medical Research Agency for the development of targeted or personalized medicine based on cell therapies or protein products (ABM/2022/5) were recommended for funding.
The projects goal is to conduct phase I clinical trials for biological molecules for use in oncology.
The amount of funding is over PLN 62 million with the value of both projects amounting to almost PLN 100 million.
The funding may be spent in the years 2022-2026.
The condition for the funds to be launched is the signing of agreements for each project recommended by ABM for funding.
Link: 🔗 The results of the competition on the MRA website (🇵🇱)